CNS Pharmaceuticals Inc. (CNSP)
0.11
0.00 (2.52%)
At close: Jan 15, 2025, 10:22 AM
undefined% (undefined)
| Bid | 0.11 |
| Market Cap | 6.17M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -299.06 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.11 |
| Volume | 3,495,113 |
| Avg. Volume (20D) | 25,015,377 |
| Open | 0.11 |
| Previous Close | 0.11 |
| Day's Range | 0.10 - 0.11 |
| 52-Week Range | 0.10 - 41.00 |
| Beta | undefined |
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2019
Employees 3
Stock Exchange NASDAQ
Ticker Symbol CNSP
Website https://www.cnspharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CNSP stock is "Buy." The 12-month stock price forecast is $0.5, which is an increase of 365.55% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
-10.02%
CNS Pharmaceuticals shares are trading higher. The...
Unlock content with
Pro Subscription
4 months ago ·
Source
+2.89%
CNS Pharma shares are trading after Maxim Group upgraded the stock from Hold to Buy and announced a $0.50 price target.
